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Abstract
Background: Maturation of human immunodeficiency virus type 1 (HIV-1) occurs upon activation of HIV-1 protease
embedded within GagProPol precursors and cleavage of Gag and GagProPol polyproteins. Although reversible oxidation
can regulate mature protease activity as well as retrovirus maturation, it is possible that the effects of oxidation on viral
maturation are mediated in whole, or part, through effects on the initial intramolecular cleavage event of GagProPol. In
order assess the effect of reversible oxidation on this event, we developed a system to isolate the first step in protease
activation involving GagProPol.
Methodology/Principal Findings: To determine if oxidation influences this step, we created a GagProPol plasmid construct
(pGPfs-1C) that encoded mutations at all cleavage sites except p2/NC, the initial cleavage site in GagProPol. pGPfs-1C was
used in an in vitro translation assay to observe the behavior of this initial step without interference from subsequent
processing events. Diamide, a sulfhydral oxidizing agent, inhibited processing at p2/NC by .60% for pGPfs-1C and was
readily reversed with the reductant, dithiothreitol. The ability to regulate processing by reversible oxidation was lost when
the cysteines of the embedded protease were mutated to alanine. Unlike mature protease, which requires only oxidation of
cys95 for inhibition, both cysteines of the embedded protease contributed to this inhibition.
Conclusions/Significance: We developed a system that can be used to study the first step in the cascade of HIV-1
GagProPol processing and show that reversible oxidation of cysteines of HIV-1 protease embedded in GagProPol can block
this initial GagProPol autoprocessing. This type of regulation may be broadly applied to the majority of retroviruses.
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Introduction
HIV-1 GagProPol autoprocessing is a unique step in the HIV
life cycle and involves the dimerization of two GagProPol
monomers and subsequent autocleavage of the polyproteins to
generate virus structural proteins as well as protease, reverse
transcriptase, and integrase [1]. This autoprocessing is usually
delayed until GagProPol and Gag polyproteins assemble at the cell
membrane and is followed by further cleavage of Gag and other
GagProPol polyproteins during and/or just after budding from the
plasma membrane [2,3]. Premature autoprocessing and activation
of protease in HIV-1 infected cells or over-expression of
GagProPol, impairs viral production and infectivity [4,5]. Similar
results have been described for Rous sarcoma virus (RSV), where a
protease-linked dimer results in premature viral processing in the
cytoplasm of infected cells in conjunction with decreased virus
production [6]. These studies indicate a need for control over the
timing of protease activation, particularly when viral expression
and therefore protease are at their highest levels.
Previous studies have demonstrated that reversible oxidation
can regulate maturation of immature HIV-1 virions [7]. One
possible way that this may occur is through modification of the
mature protease by oxidation of a cysteine at position 95 (cys95) at
the dimer interface; this could then interfere with protease
dimerization. In the case of HIV-2, reversible oxidation of
methionine 95 (met95) serves to regulate protease activity in the
same way [8,9]. For HTLV-1, two conserved cysteines at positions
90 and 109 serve a similar function [8]. The oxidative
modifications of HIV-1 and HIV-2 protease interfere with
dimerization [8,9] and it is predicted that the modifications of
HTLV-1 protease may prevent dimerization as well.
A similar process is involved in the regulation of the maturation
of Mason-Pfizer monkey virus (M-PMV) capsids [10]. M-PMV,
also a retrovirus, is unusual in that the GagPro polyproteins
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contains two methionines and one cysteine at the dimer interface,
is still not activated until the time of budding. Experimentally, the
M-PMV protease and viral maturation can be activated by the
addition of a reducing agent [10]. In fact, essentially all retroviral
proteases studied have one or more oxidizable residues at or near
the protease dimer interface with the potential to be regulated in
this manner [8]. Cellular enzymes, such as thioltransferase and
methionine sulfoxide reductase have been shown to reverse these
cysteine and methionine oxidative modifications, respectively,
leading to protease dimerization and reactivation [8,11,12]. It has
been suggested that that regulation by reversible oxidation of one
or more cysteine or methionine residues at or near the dimer
interface is a general property of retroviral proteases [8].
However, it remains unclear whether the regulation of viral
maturation by reversible oxidation is effected primarily through
oxidation of mature protease or whether the main target is the
initial autoprocessing event by the GagProPol polyprotein. The
first step in HIV-1 polyprotein processing is an intramolecular
cleavage between the p2 protein (also known as spacer peptide 1 or
SP1) domain and nucleocapsid (NC) domain or p2/NC [13–15].
This step is unique from those carried out by mature protease in
that: 1) cleavage of GagProPol in trans by exogenous protease at
the p2/NC junction is much more rapid than cleavage at p2/NC
by the dimerized precursor polyprotein [13]; 2) the initial
processing step is quite resistant to inhibition by active site
protease inhibitors when compared to mature protease [14 and
our unpublished data]; and 3) even the second cleavage carried
out by the embedded protease is 27 fold more sensitive to the
potent active site inhibitor, ritonavir, as compared to the initial
cleavage at p2/NC by the embedded protease. Due to these
differences it was unclear whether oxidation of the embedded
protease in GagProPol could reversibly inhibit the initial step in
viral maturation.
In this report, we developed a unique assay that enabled us to
isolate the initial GagProPol autoprocessing event without
interference from subsequent proteolytic events. Through modi-
fication of a GagProPol encoding plasmid, we were able to
measure the initial cleavage of GagProPol at the P2/NC site. This
allowed us to assess conditions that may control this cleavage
event. We demonstrate that the initial step in GagProPol
processing can be specifically and reversibly regulated through
oxidation of the cysteines of the embedded HIV-1 protease, and
that this regulation differs in some ways from that of mature HIV-
1 protease. The observations reported here indicate reversible
oxidation as a potential mechanism to regulate the onset of
retroviral polyprotein processing.
Results
Development of a GagProPol first-cut assay
The pGPfs, developed by Pettit et al. [13], contains a frame-shift
mutation that causes it to produce full length GagProPol but not
p55 Gag protein. The GagProPol produced by this plasmid
subsequently undergoes limited autoproteolytic processing. The
major products resulting from GagProPol autoprocessing in this
system are a result of cleavage at p2/NC and cleavage within the
transframe protein (TF) yielding MA-p2, NC-IN, NC-TF440 and
TF441-IN (Figure 1A) [13]. We were interested in studying the
initial step of polyprotein processing and in determining if this step
could be regulated by reversible oxidation. To this end, we
produced a modified construct that would only undergo the initial
step of polyprotein processing. To ensure processing at only the
p2/NC site, we incorporated blocking mutations at all other major
processing sites within pGPfs. Amino acid mutations flanking the
GagProPol processing sites were chosen based upon previous
studies indicating that these substitutions prevented proteolytic
processing (Table 1) [16-18]. In addition, alanine mutations were
placed at the processing sites flanking the N and C termini of
protease to prevent processing at these sites by the embedded
protease [13], while the protease sequence itself was conserved as
wild type (Table 1). While cleavage at these flanking sites was not
previously detected [13], these mutations provided additional
assurance that the results would not be skewed by a small amount
of this product. These modifications also reduced the likelihood
that partially processed GagProPol could cleave other polyproteins
in trans. The modified pGPfs plasmid had eight processing site
mutations and was designated as pGPfs-one cut (pGPfs-1C)
(Figure 1B).
In vitro translation was carried out using wild type (WT) pGPfs or
pGPfs-1C. As expected, in vitro translation of the WT plasmid
generated GagProPol, truncated GagProPol from internal initia-
tions (GagProPolii) and expected products of the first and second
processing steps (MA-p2, NC-IN, TF441-IN, Figure 1C)
[13,14,19]. These products (MA-p2, NC-IN, and TF441-IN) were
absent when a pGPfs containing a D25A mutation in the protease
gene that inactivates the embedded protease (pGPfs-PR D25A)
was utilized (Figure 1C, lane 2). A number of weaker non-specific
bands were also produced by the WT pGPfs, similar to those seen
previously [13,14,19]. Most of these weaker bands are unrelated to
GagProPol processing as they are generated both when using
GagProPol plasmids encoding inactive as well as active protease
(Figure 1C, lane 2 and 5). Addition of purified HIV-1 protease
(15 min incubation) to pGPfs-PR D25A yielded the major products
MA-p2,NC-INand a band tentatively identified asPR-IN basedon
studies reported previously (Figure 1C, lane 3) [13].
In contrast to the results with WT pGPfs, in vitro translation of
pGPfs-1C yielded only the major products of the first processing
step and these aligned with the previously identified products
obtained from WT pGPfs, namely MA-p2 and NC-IN (Figure 1C,
lane 4). In particular, pGPfs-1C did not generate any of the
additional processing intermediates that were seen with pGPfs. To
confirm that the products from pGPfs-1C processing were indeed
due to processing by the embedded protease, we created a D25A
mutation in the protease region of pGPfs-1C and designated the
plasmid containing inactive protease as pGPfs-1C-PR D25A. In
vitro translation of pGPfs-1C-PR D25A produced full length
GagProPol (and GagProPolii) but did not produce any cleavage
products (Figure 1C, lane 5). As expected, addition of purified
HIV-1 protease for 15 minutes (250 nM dimer) to the sample
producing D25A GagProPol resulted in almost complete process-
ing only at the p2/NC cut site (Figure 1C, lane 6). To further
verify that processing was occurring at the p2/NC cut site, we
generated a plasmid encoding MA/CA/p2 and used it as a
standard in the in vitro translation assay. The protein product
generated from this plasmid (MA-p2) migrated to the same position
on the gel as the small product generated from the GagProPol
encoded by the first cut plasmid (Figure 1C, lane 7). These studies
indicated that in vitro translation of pGPfs-1C produced GagProPol
that undergoes a single cleavage event at p2/NC.
The rate of processing at the initial cleavage site was
investigated in a time course experiment. Approximately 60% of
the pGPfs-1C GagProPol underwent cleavage at the p2/NC
within 45 minutes and 90% underwent cleavage within 75
minutes, at which time it reached a plateau (Figure 2 and Figure
S1). After two hours of incubation, minor bands below the large
product were evident but these represented less than 5% of the
total products produced (data not shown). These likely represent
GagProPol Processing
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the action of the embedded protease within the large product (NC-
IN). These data indicate the embedded HIV-1 protease readily
cleaves within pGPfs-1C GagProPol at the p2/NC junction
yielding MA-p2 and NC-IN products and that the blocking
mutations do not adversely affect processing at the initial site.
However, the presence of blocking mutations prevents any
significant processing of the polyprotein at the other cleavage sites.
Inhibition of the initial step in GagProPol Processing by
oxidation is dependent on the cysteines of HIV-1
protease
We previously demonstrated that HIV-1 protease could be
regulated by reversible oxidation of the conserved cysteines of
HIV-1 protease and found that exposure of immature HIV-1
virions to oxidizing agents could inhibit viral maturation [7,11,20].
This inhibition required the presence of cys95, but not cys67, since
replacing cys95 with alanine led to processing even in the presence
of oxidizing agents, while replacing cys67 with alanine had no
substantial effect [20]. However, it was unclear if oxidation could
similarly affect the action of the embedded protease at the initial
step of GagProPol processing. To determine if the initial step in
GagProPol processing was sensitive to oxidation, we examined the
effect of oxidants on GagProPol processing using pGPfs-1C. Initial
studies revealed that hydrogen peroxide (1–10 mM), a nonspecific
oxidizing agent, caused partial inhibition of GagProPol processing
in a cysteine-dependent manner (data not shown). However,
higher concentrations of hydrogen peroxide were detrimental to
the translation system, thereby preventing any further assessment
on GagProPol processing. Diamide is a thiol-oxidizing agent that
can create mixed disulfide bonds between proteins and low
molecular weight thiols and therefore we tested the effect of
diamide on GagProPol processing [21,22]. In the absence of
diamide, processing with pGPfs-1C proceeded almost to comple-
tion as evidenced by the presence of the two GagProPol processing
products and the absence of full length GagProPol (Figure 3, lane
1). However, in the presence of diamide, GagProPol processing
was inhibited in a dose-dependent fashion at concentrations that
only had a minor effect on the in vitro translation system as
evidenced by the total product produced in the reactions (Figure 3,
lanes 2–5). By contrast, the effect of diamide on the processing of
pGPfs-1C C67A, C95A GagProPol was much less pronounced
(Figure 3, lanes 6–10). These data indicate that the cysteines of
HIV-1 protease are particularly susceptible to diamide oxidation
and this oxidation leads to inhibition of the initial cleavage event.
To assess the contribution of each cysteine within the embedded
protease to inhibition of processing by diamide, we examined
GagProPol processing for the plasmid constructs pGPfs-1C,
pGPfs-1C C95A, pGPfs-1C C67A and pGPfs-1C C67A C95A
in the presence and absence of 1 mM diamide. In the absence of
diamide, all four GagProPols underwent substantial processing,
although there were some small differences among them. Of note,
the plasmids retaining cys95 (pGPfs-1C and pGPfs-1C C67A)
Figure 1. Schematic diagram for the GagProPol polyprotein
precursor generated from pGPfs, the polyprotein precursor
generated from pGPfs-1C and results of GagProPol proteolytic
processing of pGPfs (WT) and pGPfs-1C. A) The GagProPol
plasmid construct, pGPfs, encodes a 162 kDa polyprotein. The
processing sites for the polyprotein are indicated with vertical lines.
The location of the first cut site (p2/NC) is indicated with an arrow. The
known secondary cut site (occurring between amino acids 440 and 441
within the transframe protein) is indicated by a dotted line. The
resultant products from cleavages at these two sites are indicated. B)
The schematic for pGPfs-1C (modified pGPfs plasmid) showing the sites
for the blocking mutations designated with an X. C) In vitro
transcription/translation with
35S-methionine was carried out for 1 h
in the presence of the indicated plasmid construct. Note that plasmids
pGPfs-PR D25A and pGPfs-1C-PR D25A encode a protease with a D25A
mutation rendering it inactive. pMA/CA/p2, yields the small product
(MA-p2) fragment and was used to verify the MA-p2 fragment.
Exogenous HIV-1 protease provided in trans (trans-prot, 250 nM) was
added to pGPfs-PR D25A or pGPfs-1C-PR D25A constructs following
45 min of translation and was terminated 15 minutes later with 3X LDS
sample buffer. Samples were separated by LDS-PAGE and visualized by
autoradiography. The location for GagProPol, the internal initiation
GagProPol (GagProPol ii) and the products of GagProPol processing
(MA-p2, NC-IN, TF441-IN, and PR-IN) occurring through the action of the
embedded protease or the exogenous protease are indicated in the
figure.
doi:10.1371/journal.pone.0013595.g001
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Processing site Nucleotide sequence Amino acid sequence
p17/p24 WT CAA AAT TAC/CCT ATA GTG Gln Asn Tyr/Pro Ile Val
p17/p24 Mut CAA AAT ATC/CTT ATA GTG Gln Asn Ile/Leu Ile Val
p24/p2 WT AGA GTT TTG/GCT GAA GCA Arg Val Leu/Ala Glu Ala
p24/p2 Mut AGA GTT GTG/GCT GAA GCA Arg Val Val/Ala Glu Ala
NC/TF WT CAG GCT AAC/TTC CTC CGC Gln Ala Asn/Phe Leu Arg
NC/TF Mut CAG GCT ATC/GAT CTC CGC Gln Ala Ile/Asp Leu Arg
TF440/441 WT TTG GCC TTC/CTA CAA GGG Leu Ala Phe/Leu Gln Gly
TF440/441 Mut TTG GCC ATC/CTA CAA GGG Leu Ala Ile/Leu Gln Gly
TF/Protease WT TTT AAC TTC/CCT CAG GTC Phe Asn Phe/Pro Gln Val
TF/Protease Mut GCG GCC GCC/CCT CAG GTC Ala Ala Ala/Pro Gln Val
Protease/Pol WT TTA AAT TTT/CCC ATT AGC Leu Asn Phe/Pro Ile Ser
Protease/Pol Mut TTA AAT TTT/GCT GCA GCC Leu Asn Phe/Ala Ala Ala
Pol/RNaseH WT GAA ACC TTC/TAT GTA GAT Glu Thr Phe/Tyr Val Asp
Pol/RNaseH Mut GAA ACC ATC/TAC GTA GAT Glu Thr Ile/Tyr Val Asp
RNaseH/Integrase WT AAA GTA CTA/TTT TTA GAT Lys Val Leu/Phe Leu Asp
RNaseH/Integrase Mut AAA GTA ATA/TTT TTA GAT Lys Val Ile/Phe Leu Asp
Protease Mutations Nucleotide sequence Amino acid sequence
D25 WT CTA TTA GAT ACA GGA Leu Leu Asp Thr Gly
A25 Mut CTA TTG GCC ACA GGA Leu Leu Ala Thr Gly
C67 WT GAA ATC TGT GGA CAT Glu Ile Cys Gly His
A67 Mut GAA ATC GCC GGA CAT Glu Ile Ala Gly His
C95 WT ATT GGT TGC ACT TTA Ile Gly Cys Thr Leu
A95 Mut ATT GGT GCA ACT TTA Ile Gly Ala Thr Leu
doi:10.1371/journal.pone.0013595.t001
Figure 2. Time course for pGPfs-1C GagProPol processing. In
vitro transcription translation with
35S-methionine was carried out for
45, 60, 75 and 90 minutes. Samples were separated by LDS-PAGE and
visualized by autoradiography and the percent processing determined
using densitometry. The precursors (GagProPol and GagProPolii) and
two products (MA-p2, NC-IN) were scanned and the extent of
processing calculated as a percent: [(products)/(precursor plus prod-
ucts) x 100]. The LDS-PAGE for this data is shown Figure S1.
doi:10.1371/journal.pone.0013595.g002
Figure 3. Dose dependent inhibition of pGPfs-1C GagProPol
and pGPfs-1C C67A/C95A GagProPol processing by diamide. In
vitro transcription/translation with
35S-methionine was carried out in
the presence of increasing concentrations of the sulfhydral oxidant
diamide (A) pGPfs-1C (lanes 1–5) or the double cysteine mutant
construct pGPfs-1C C67A/C95A (lanes 6–10). Samples were separated
by LDS-PAGE and visualized by autoradiography. The precursors
(GagProPol and GagProPolii) and products (MA-p2, NC-IN) of GagProPol
processing by the embedded protease are indicated.
doi:10.1371/journal.pone.0013595.g003
GagProPol Processing
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plasmids lacking cys95 (pGPfs-1C C95A pGPfs-1C C67A C95A)
had some residual unprocessed GagProPol remaining (Figure 4A,
lanes 3 and 7). This was a consistent finding throughout our
studies and indicates that the presence of cys95 is important for
maximally efficient cleavage of GagProPol at p2/NC. Diamide
(1 mM) substantially inhibited processing of pGPfs-1C GagProPol,
but was less effective on each of the single cysteine mutants
(Figure 4A, lanes 1–6) and was the least effective at inhibiting
processing of the double cysteine mutant GagProPol produced
from pGPfs-1C C67A, C95A (Figure 4A, lanes 7–8). Thus, the loss
of either cysteine significantly impaired the ability of diamide to
block processing. To quantify this effect among the different
plasmids and correct for internal differences in translation and
processing of the alanine mutants, densitometry was performed on
the unprocessed GagProPol bands and product bands from four
separate experiments. The extent of processing was first calculated
for the untreated controls and then compared to processing
following treatment with 1 mM diamide. As shown in Figure 4B,
diamide inhibited the processing of GagProPol produced from
pGPfs-1C about 65% while processing for C95A, C67A and the
double mutant was inhibited by 35%, 42%, and 10%, respectively
(Figure 4B). These data demonstrate that optimal inhibition of
GagProPol processing by diamide requires the presence of both
cys67 and cys95.
Oxidative inhibition of the initial step in GagProPol
processing is reversible
Next, we wanted to assess the ability of DTT, a sulfhydral
reducing agent, to restore processing after inhibition by diamide
treatment. To determine if DTT could reverse the inhibition of
GagProPol processing after an initial diamide treatment, the in vitro
translation reaction was first carried out for 45 minutes in the
absence or presence of 1 mM diamide. Following this, samples
were treated with 0, 1, 10, or 20 mM DTT and the reaction was
allowed to proceed for 15 more minutes. DTT reversed the
diamide-induced inhibition of GagProPol processing at the first
cut site (p2/NC) and did so in a dose dependent manner
(Figure 5A, lanes 1–5). There was a low level of diamide induced
inhibition of processing for the double cysteine mutant pGPfs-C
C67A, C95A but this was restored following DTT treatment
(Figure 5A, lanes 6–10). Densitometric analyses were done to
assess the extent of reversal of diamide inhibited GagProPol
processing for pGPfs-1C for three separate experiments. As shown
in Figure 5B, diamide inhibited 60% of the processing and much
of this (67%) was restored with as little as 1 mM DTT and almost
90% was restored with 20 mM DTT (Figure 5B). Overall, these
data indicate that diamide oxidation of the cysteines within the
embedded protease leads to inhibition of the initial cleavage step in
GagProPol polyprotein processing and this inhibition can be
readily reversed with reducing agent.
We also investigated the ability of DTT to reverse the diamide-
induced inhibition of GagProPol processing for the single cysteine
mutants. Once again, diamide blocked the majority of GagProPol
processing obtained with pGPfs-1C, but was somewhat less
effective at blocking GagProPol processing obtained with single
cysteine mutant C67A or C95A pGPfs-1Cs (Figure 6A, lanes
2,5,9). Addition of 1 mM DTT, following inhibition by diamide,
restored processing in all cases (Figure 6A, lanes 3,6,and 9).
Although processing for pGPfs-1C C67A and pGPfs-1C C95A
were similarly inhibited by diamide, restoration of processing with
1 mM DTT was most efficient with pGPfs-1C C67A, and similar
to the reversal obtained for pGPfs-1C (Figure 5A). Based on
densitometric analysis, DTT restored about 60% of the processing
inhibited by diamide (Figure 6B). A similar improvement in
GagProPol processing was seen with pGPfs-1C C67A that
contains protease with cys95 intact (Figure 6B). However, DTT
only restored an average of 40% of processing for the pGPfs-1C
C95A GagProPol containing protease with cys67, although this
lower level of processing was not statistically significant when
compared to the other plasmids (Figure 6B). Together, these data
suggest that oxidation of both cysteines can be reversed with DTT.
However, cys67 may be more difficult to reverse when compared
to cys95 of the embedded protease in GagProPol in the context of
the single cysteine mutants.
Figure 4. Inhibition of GagProPol processing by the oxidant
diamide is dependent on both cysteines of the embedded HIV-
1 protease. (A) In vitro transcription/translation with
35S-methionine
was carried out for 1 h in the absence (2) or presence (+)o f1m M
diamide. Samples were separated by LDS-PAGE and visualized by
autoradiography. The precursors and products of GagProPol processing
by the embedded protease are indicated. The pGPfs-1C plasmid
construct used is indicated above the wells. (B) Densitometry was
carried out on autoradiograms from 4 separate experiments under the
conditions as described for Figure 4A and the extent of inhibition of
processing calculated. The percent inhibition was calculated as
(processing without diamide-processing with diamide)/(processing
without diamide) x 100. Percent processing is calculated as in
Figure 2. Values represent the average +/2 the standard deviation
from 4 independent experiments.
doi:10.1371/journal.pone.0013595.g004
GagProPol Processing
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Previous studies demonstrated that reversible oxidation inhib-
ited HIV-1 maturation through the inhibition of protease activity
and that the activity of mature protease could be regulated by such
oxidation of residues at the dimer interface, thus interfering with
dimerization[7,8,23]. However, the initial dimerization of HIV
protease takes place between two GagProPol monomers that, after
dimerization, undergo autoprocessing through the action of the
embedded protease of the polyprotein. We hypothesized that
regulation of this initial step by reversible oxidation of the dimer
interface of GagProPol may account for much or all of the
regulation of HIV viral maturation by redox changes. To explore
this hypothesis, we used an in vitro GagProPol translation assay
system to isolate the dimerization and first step in HIV-1
polyprotein processing. Our modified GagProPol plasmid con-
struct yielded GagProPol that efficiently underwent dimerization
and autocleavage at p2/NC without further processing taking
place. Using this construct we found that autocleavage at p2/NC
within GagProPol was quite sensitive to oxidation by the sulfhydral
oxidant, diamide and this was readily reversible with reducing
agent. The ability to regulate processing by reversible oxidation
was lost when the cysteines of the embedded protease were
mutated to alanine and processing proceeded irrespective to the
addition of diamide. Although we could not determine the precise
mechanism of inhibition using this assay, we suggest that the
oxidative modification of cysteines in the embedded protease
interferes with GagProPol dimerization, similar to that previously
demonstrated for mature protease [8,9]. Diamide oxidation also
blocked the processing for pGPfs-1C C67A/C95A although this
Figure 5. Dose response restoration of polyprotein processing
by DTT following inhibition of pGPfs-1C or pGPfs-1C
C67A,C95A processing by diamide. A) In vitro transcription/
translation was carried out with pGPfs-1C (lanes 1–5) or pGPfs-1C
C67A,C95A (lanes 6–10) in the absence (2) or presence (+)o f1m M
diamide for 45 min followed by addition 1, 10, or 20 mM DTT for 15
minutes as shown above each lane. Samples were separated by LDS-
PAGE and analyzed by autoradiography. The precursors and products of
GagProPol processing by the embedded protease are indicated. B)
Densitometry was carried out on autoradiograms from 3 separate
experiments under the conditions as described for Figure 5A. The
percent inhibition of processing was calculated and plotted. for pGPfs-
1C (n) solid line and pGPfs-1C C67A,C95A (l) dotted line. The following
formula was used: Percent inhibition of processing = (processing
without diamide-processing with diamide and 0–20 mM DTT)/(process-
ing without diamide) x 100. The values represent the average +/2 the
standard deviation for 3 independent experiments.
doi:10.1371/journal.pone.0013595.g005
Figure 6. Restoration of polyprotein processing by DTT
following inhibition of pGPfs-1C, pGPfs C95A, or pGPfs C67A
processing by diamide. A) In vitro transcription/translation was
carried out for pGPfs-1C, pGPfs C95A, or pGPfs C67A in the absence (2)
or presence (+) of 1 mM diamide for 45 min followed by addition of
1 mM DTT. Samples were incubated for an additional 15 min to allow
for processing to take place and then separated by LDS-PAGE and
analyzed by autoradiography. The precursors and products of
GagProPol processing by the embedded protease are indicated. B)
Densitometry was carried out on autoradiograms from 3 separate
experiments under the conditions as described for Figure 6A. The
percent processing restored was calculated as (processing with DTT and
diamide-processing with diamide)/(processing without DTT or diamide-
processing with diamide) x 100. The values represent the average +/2
the standard deviation for 3 independent experiments.
doi:10.1371/journal.pone.0013595.g006
GagProPol Processing
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encoding a cysteine containing protease. The fact that the low
level of inhibition with the double mutant was reversible with
DTT (see Figure 5) suggests that other cysteines within the
GagProPol also participate to some degree in the inhibition of
processing. It has been reported that the nucleocapsid domain
contains reactive cysteine residues which, when oxidized, revers-
ibly affect polyprotein processing [24]. Therefore these residues
may also play a partial role in the inhibition of GagProPol
processing observed with diamide treatment.
There were some key differences between the effects of
oxidation on the embedded protease and those observed for
mature protease. For mature HIV-1 protease, oxidation of cys95
alone was sufficient to inactivate the enzyme and viral maturation
[11,20]. In contrast, the presence of both cysteines (67 and 95) was
required to obtain maximum inhibition/regulation of the initial
GagProPol processing step. Also, while oxidation of cys67 of
mature protease by glutathionylation increased activity and
stabilized the enzyme, oxidation of cys67 of the embedded
protease within the in vitro translation system led to partial
inhibition of GagProPol processing [11,20]. This difference in the
effect of cys67 oxidation of the embedded protease as compared to
the mature protease is likely related to differences in the
conformation of protease in GagProPol dimers compared to those
for mature dimers. For mature protease, it is more difficult to
reverse oxidation of cys67 versus that for cys95 [11]. While
oxidation of cys95 in mature WT protease or C67A protease
results in complete inactivation of the enzyme [11,20] and
inhibition of protease dimerization [8,9], oxidation of GagProPol
containing only cys95 leads only to partial inhibition of processing.
Thus, as suggested previously [13], sequences within GagProPol
that lie outside of the protease region may partially compensate for
disruption of the protease dimeric interaction. We cannot rule out
that the mutations that were made to prevent cleavage at
subsequent processing sites had some influence on the differences
observed between oxidation of endogenous and versus exogenous
protease.
Reversible oxidation of certain amino acids of retroviral
proteases has been suggested as one potential mechanism for
preventing premature activation of the protease [8,10]. Studies
with immature HIV-1 virions produced by exposure to a protease
inhibitor demonstrated that reducing agents could increase viral
processing following removal of the inhibitor [7]. Similarly,
immature capsids of M-PMV undergo proteolytic processing
following the addition of reducing agent [10]. These studies
implicated protease oxidation as a mechanism to inhibit protease
activation. Our studies here demonstrate clearly that reversible
oxidation can regulate the onset of the polyprotein processing
cascade for HIV-1.
Evidence for the importance of redox-mediated regulation of
protease and/or protease precursors is strongest in the case of M-
PMV, in which the GagPro polyproteins assemble in the
cytoplasm but do not mature until the time of budding [10].
However, similar regulation of retroviral protease has been shown
for several other retroviruses, and essentially all retroviruses
studied have at least one cysteine or methionine in the region of
the dimer interface, suggesting that this regulation is constrained
by viral evolution and therefore important in the retroviral
lifecycle [7–9]. In the laboratory, HIV-1 does not require the
presence of cys67 or cys95 to generate infectious virions from
infected cells [7]. Nonetheless, cys67 and cys95 are highly
conserved among HIV-1 isolates [25]. Therefore, for HIV-1, it
is possible that the regulation of the initial step in processing by
reversible oxidation may only be necessary in certain cell types or
under certain conditions, such as those involving oxidative stress.
Virus infection, including HIV-1 infection, leads to a state of
oxidative stress in certain cell types and this is known to enhance
HIV-1 replication through the activation of NF-kB [26–29].
Oxidative environments, like those encountered in infected cells
[26,30], could lead to reversible cysteine oxidation of the
embedded protease and as a result prevent premature protease
activation and premature cell death when GagProPol is accumu-
lating to high levels in the cell. Thus, the presence of cysteines
within protease may optimize viral production by preventing
deleterious effects of the protease on the infected cells. This effect
may be particularly important in cells that produce virus for
extended periods of time such as monocytes/macrophages. By
contrast, the D-type retroviruses, such as M-PMV, may utilize
reversible oxidation as the primary means to control protease
activity as evidenced by the lack of particle processing in the
absence of reducing agent and the activation of such processing
with reducing agent [10].
The initial GagProPol processing step provides an additional
target for the development of inhibitors of viral replication, a step
separate from the processes mediated by the mature protease.
While intramolecular enzymatic steps are inherently more difficult
to inhibit through a classical mode of competitive inhibition as
compared to trans cleavage [14 and references therein], it may be
possible to develop inhibitors of GagProPol dimerization that
could prevent protease activation and autoprocessing. It is possible
the observed diamide inhibition of GagProPol processing in this
study results from the inhibition of GagProPol dimerization,
although further studies will be necessary to determine this. Recent
studies have provided evidence that darunavir and similar
compounds have the ability to block protease dimerization within
cells [31]. We are currently screening active site inhibitors in this
assay to determine what structural properties might favor
inhibition of the initial processing step and how these properties
relate to their ability to block protease activity and protease
dimerization. Moreover, compounds designed as dimerization
inhibitors of protease can be screened to assess their potential as
inhibitors of the initial processing step. It may be more feasible to
inhibit the dimerization of GagProPol than to reverse the
dimerization of the mature protease dimer considering the low
dissociation constant of mature protease [32]. Such studies can
provide an additional target for the pursuit of new therapies,
especially in the treatment of multi-drug resistant HIV [33].
Materials and Methods
Plasmid construction and mutagenesis
The plasmids pGPfs and pGPfs-PR D25Awere obtained from
Dr. Ronald Swanstrom (UNC-Chapel Hill, NC). pGPfs contains a
T7 promoter and has a forced frame-shift mutation leading to the
production of full length GagProPol in an in vitro translation system
[13]. pGPfs-PR D25A contains a D25A mutation in the protease
coding region to inactivate protease activity and prevent
proteolytic processing of the GagProPol precursor generated
during in vitro translation. Further mutations were introduced into
pGPfs by site directed mutagenesis using a Stratagene Quik-
Change Multi Site-Directed Mutagenesis Kit. The primers used to
introduce processing site and protease mutations are shown in
Table 1. A DNA fragment encoding the matrix-capsid-p2
polyprotein (MA-p2) was produced using PCR to add NdeI and
BamHI restriction sites [34]. This DNA fragment was then ligated
into expression vector pET11 creating plasmid pMA/CA/p2 and
its product was used as a control to verify the identity of the small
product from the first processing step. Plasmids were also
GagProPol Processing
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and/or a D25A mutation introduced in the protease-coding region
of pGPfs-1C. The primers used for these constructs are shown in
Table 1.
In-vitro translation reactions for studying GagProPol
proteolytic processing
Transcription and translation reactions were performed similar
to those described previously using a TnT T7 Coupled
Reticulocyte Lysate System (Promega) except when noted below
[13]. The reactions (25 mL) were carried out with Easy-Tag L-
35S-
methionine (.1000Ci/mM, Perkin Elmer) rather than
35S-
cysteine. This was done since there are a similar number of
methionines in the two products from the first cut and therefore
they would yield bands with similar intensity in the autoradio-
grams. In addition, mutating the cysteines of the encoded protease
would not alter the intensity of the product bands in experiments
using these constructs. A master mix was prepared using the TnT
rabbit reticulocyte lysate (RRL), reaction buffer, T7 polymerase,
and amino acid mixture (minus methionine) provided with the
system at ratios suggested by the technical bulletin. Additionally,
RNasin Ribonuclease Inhibitor (Promega) was added to the
master mix at 1 mL per 25 mL reaction mixture. Nuclease-free
DEPC water was used to bring the final volume of each reaction to
25 mL. The master mix was incubated on a heat block for 15
minute at 30uC. The DNA plasmid constructs were added to the
master mix at 0.5 mg/reaction or at 0.125 mg/reaction for pMA/
CA/p2. When multiple plasmids were tested in the same
experiment, the master mix was distributed among the treatment
wells before the addition of DNA. Purified HIV-1 protease was
prepared as described previously [35] and when indicated added
at a final concentration of 250 nM active protease dimer. After
incubation at 30uC, an equal volume of 3x lithium dodecyl sulfate-
polyacrylamide gel electrophoresis (LDS-PAGE) loading buffer
containing 150 mM dithiothreitol (DTT) (Invitrogen) was added
to each reaction tube and the samples were heated at 70uC for 15
minutes. The samples were cooled at room temperature for 30
minutes and then loaded onto a 1 mm 10-well 4–12% Bis-Tris
NuPAGE gel (Invitrogen). The gel was run at 100 volts for the first
10 minutes and then run at 200 volts for 70 minutes. The gel was
washed in the following sequence; distilled water for 10 minutes,
10% acetic acid for 30 minutes, 8–10 washes with distilled water,
and finally 10% glycerol for 15 minutes. Subsequently, the gel was
placed under a conventional dryer/vacuum for 90 minutes at
54uC and exposed to film for autoradiography using Kodak
Scientific Imaging film (Kodak). For quantification, GagProPol
related bands on the film were scanned and densitometry
performed using Un-Scan-It (Silk Scientific Corporation). Ratios
of product formation to total GagProPol protein production
(substrates and products) for each sample were determined, thus
correcting for any internal differences in the overall extent of
translated GagProPol protein that was obtained for each sample.
Supporting Information
Figure S1 In vitro transcription/translation with 35S-methio-
nine was carried out for 45, 60, 75 and 90 minutes without (lanes
1,3,5,and 7) or with (lanes 2,4,6, and 8) 1 mM DTT. Samples
were separated by LDS-PAGE and visualized by autoradiography
and the percent processing determined using densitometry. The
precursors (GagProPol and GagProPolii) and two products (MA-
p2, NC-IN) are indicated.
Found at: doi:10.1371/journal.pone.0013595.s001 (2.18 MB TIF)
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